Active Biotech begins enrollment for study of Anyara with Taxotere as lung cancer treatment

By E. Janene Geiss

Philadelphia, Nov. 8 - Active Biotech said Tuesday that it began enrollment for a clinical phase I combination study of its drug candidate Anyara with the chemotherapy drug Taxotere to treat lung cancer.

The dose-escalation study is designed to evaluate the two drugs in combination for the treatment of non-small cell lung cancer, according to a company news release.

The company said it expects to enroll 20 to 30 patients at clinics in the United States, Denmark and Russia.

The study will examine the response to increasing doses of Anyara in combination with a fixed dose of Taxotere, which will be administered according to an established dosing schedule. Anyara will be dosed at levels expected to have an anti-tumor effect, officials said.

Lund, Sweden-based Active also is conducting a clinical phase I dose-escalation study of Anyara only in the United States, Norway and the U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.